← Back

Jiangsu Bioperfectus Technologies Co Ltd

688399.CGCNY
29.92-56.7%1Y · CNY

Jiangsu Bioperfectus Technologies Co., Ltd. is a molecular diagnostics company engaged in the research, development, production, and sale of in vitro diagnostic products in China. It offers in vitro diagnostic reagents, supporting testing equipment, and in vitro testing services. Its offerings include HPV and cervical cancer testing, respiratory infection detection, infectious diarrhea solutions, and STI detection for reproductive tract infections, along with technology platforms such as nucleic acid detection, NGS, POCT, mass spectrometry, and automated control and detection. Founded in 2010, the company is headquartered in Taizhou, China.

Price · split & dividend adjusted
News & notes moving 688399.CG
China
Biotech & Genomic Medicine▼4

Board Rejects Shareholder's Proposal for Extraordinary General Meeting at Bioperfectus Technologies; Seal Validity Dispute Draws Attention

Bioperfectus Technologies announced on October 8 that the eighteenth meeting of its third board of directors was held on October 2, 2026, to review the proposal on agreeing to the controlling shareholder's request to convene an extraordinary general meeting. The result was 4 votes in favor, 5 against, and 0 abstentions, so the proposal was not passed. Directors who voted against included Wang Guoqiang, Liang Kecheng, Guo Haitao, Jia Zhaoqiang, and independent director Liu Xiaolun. Wang Guoqiang's main reason for opposition was that the controlling shareholder's relevant documents are subject to a dispute over seal validity, and the lawsuit for dissolution of the controlling shareholder is still pending, which could have a major impact on the company's control. The reasons given by the other opposing directors also involved the seal validity dispute and information asymmetry. The company also received a regulatory work letter from the Shanghai Stock Exchange, with the matter for handling being precisely the board resolution and related issues. In the first half of 2026, Bioperfectus Technologies achieved revenue of 147 million yuan and net profit attributable to the parent company of 19.56 million yuan.
Jiangsu Bioper… ▼
Biotech & Genomic Medicine
About megatrends
Biotech & Genomic Medicine › Diagnostics & Precision Testing Capital
688399.CG · Regulation · Negative Board rejected the controlling shareholder's request to convene an extraordinary general meeting amid a seal-validity dispute and an ongoing dissolution lawsuit, and the Shanghai Stock Exchange issued a regulatory work letter on the matter.
Read original ↗
财中社·2dRead more →
China
688399.CG

Bioperfectus Technologies H1 Revenue Falls 16%, Net Profit Attributable to Parent Jumps 390%

Bioperfectus Technologies released its 2026 interim report on August 27. First-half operating revenue was 147 million yuan, down 16.0% year on year. Net profit attributable to the parent was 19.56 million yuan, up 390.0% year on year. Net profit attributable to the parent excluding non-recurring items narrowed from a loss of 28.05 million yuan a year earlier to a loss of 19.17 million yuan. Net operating cash flow was negative 4.82 million yuan, down 737.5% year on year. Earnings per share were 0.1576 yuan. In the second quarter, operating revenue was 68.84 million yuan, down 18.0% year on year. Net profit attributable to the parent narrowed from a loss of 8.83 million yuan a year earlier to a loss of 1.56 million yuan. Net profit attributable to the parent excluding non-recurring items narrowed from a loss of 22.47 million yuan a year earlier to a loss of 15.16 million yuan. As of the end of the second quarter, total assets were 3.721 billion yuan, up 4.7% from the end of the previous year. Net assets attributable to the parent were 2.944 billion yuan, up 0.5% from the end of the previous year. The company focuses on the research, production and sales of in vitro diagnostic products, and has expanded into in vitro testing services, implementing an integrated business model of reagents, instruments and services.
Jiangsu Bioper…
688399.CG · Capital · Neutral H1 revenue fell 16% but net profit attributable to parent jumped 390%, with mixed signals on profitability and cash flow.
Read original ↗
财中社·45dRead more →
688399.CG▼3

Majority Shareholder of Bioperfectus Technologies Sued for Dissolution, Control May Shift Again

The majority shareholder of Bioperfectus Technologies, Shaoxing Runkang Biomedical Equity Investment Partnership, has been sued for dissolution by limited partner Liang Xilin, potentially triggering another change in company control. Previously, on July 29, the original actual controllers Fang Yongsheng, Liang Xilin, and Wang Guoqiang terminated their decade-long concerted action agreement, reducing the actual controllers from three to just Fang Yongsheng. The combined stake of the majority shareholder and its concerted parties fell from 40.97 percent to 32.24 percent. Liang Xilin holds a 71.88 percent share in Runkang Biomedical and filed the lawsuit on the grounds that the partnership's purpose cannot be achieved. If the court supports the dissolution request, it could lead to another change in the company's majority shareholder and actual controller. Affected by the unstable control situation and a broader market decline, Bioperfectus Technologies shares plunged on July 30, dropping more than 9 percent intraday to hit a new phase low. The company stated that all business operations are proceeding normally and the lawsuit has not yet adversely affected profits.
Jiangsu Bioper… ▼
688399.CG · Regulation · Negative Majority shareholder sued for dissolution, risking another control change and causing stock plunge.
Read original ↗
读创财经·73dRead more →
688399.CG▼

Shuoshi Bio's Decade-Long Concerted Action Abruptly Terminated; Controlling Shareholder Sued by Investor for Dissolution

Shuoshi Bio's former actual controllers Fang Yongsheng, Liang Xilin, and Wang Guoqiang signed an agreement on July 29 to prematurely terminate their concerted action relationship that had lasted over a decade, making Fang Yongsheng the company's sole actual controller. Although Fang Yongsheng does not hold shares directly, as the executive partner of the controlling shareholder Runkang Bio and several partnerships, he collectively controls the voting rights of 40.02 million company shares, representing 32.24% of the total share capital. Liang Xilin, as the main investor holding a 71.88% stake in Runkang Bio, has filed a lawsuit seeking the dissolution of Runkang Bio on the grounds that the partnership's purpose cannot be achieved; Fang Yongsheng holds only a 7.99% stake in Runkang Bio but controls the holding platform as executive partner. The Shanghai Stock Exchange has issued a regulatory work letter to Shuoshi Bio regarding the change in control, while the company's first-quarter 2026 non-recurring net loss was 4.01 million yuan, with operations remaining under pressure.
Jiangsu Bioper… ▼
闰康生物 · Regulation · Negative Runkang Bio is being sued for dissolution by a major investor, and its control structure is disrupted.
688399.CG · Regulation · Negative Controlling shareholder sued for dissolution and concerted action terminated, with regulatory scrutiny from Shanghai Stock Exchange.
Read original ↗
CLS·74dRead more →